EU/3/16/1769: Orphan designation for the treatment of sickle cell disease

2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (voxelotor)


On 18 November 2016, orphan designation (EU/3/16/1769) was granted by the European Commission to SynteractHCR Deutschland GmbH, Germany, for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (also known as GBT440) for the treatment of sickle cell disease.

This medicine is now known as voxelotor.

The sponsorship was transferred to Global Blood Therapeutics Netherlands B.V., the Netherlands in January 2021.

Voxelotor has been authorised in the EU as Oxbryta since 14 February 2022.

Key facts

Active substance
2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (voxelotor)
Intended use
Treatment of sickle cell disease
Orphan designation status
EU designation number
Date of designation

Global Blood Therapeutics Netherlands B.V.
Strawinskylaan 3051
1077 ZX Amsterdam 
Tel: +31203030201

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Oxbryta at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF icon orphan medicine assessment report .

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating